phrykt

Angiodynamics Inc (ANGO): who owns it and who trades it

As of Nov 16, 2026, ANGO insiders reported 3 open-market sales worth $655K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Warren Nighan JR (Vice president), with $344K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Angiodynamics

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ANGO

162 funds and institutions reported ANGO shares worth $502M at the end of Q2 2026, about 94% of the company. The largest holder is BlackRock, Inc. with 9.2%.

Funds and institutions (13F) 94%Everyone else 6%

10 largest owners, by share of the company

BlackRock, Inc.9.2%
Point72 Asset Management, L.P.7.4%
Systematic Financial Management LP6.4%
Armistice Capital, LLC5.3%
Royce & Associates LP4.8%
Broadfin Holdings LLC4.4%
Vanguard Capital Management LLC4.1%
Weber Capital Management LLC3.3%
Nuveen, LLC2.9%
Geode Capital Management, LLC2.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.3.80M9.20%$49.5M+3%
Point72 Asset Management, L.P.3.06M7.41%$39.8M-4%
Systematic Financial Management LP2.64M6.39%$34.3M+8%
Armistice Capital, LLC2.20M5.32%$28.6M+18%
Royce & Associates LP1.97M4.77%$25.6M+29%
Broadfin Holdings LLC1.82M4.40%$23.7M-12%
Vanguard Capital Management LLC1.69M4.10%$22M-2%
Weber Capital Management LLC1.36M3.28%$17.6M-1%
Nuveen, LLC1.20M2.90%$15.6M-1%
Geode Capital Management, LLC1.02M2.47%$13.3M+4%
Dimensional Fund Advisors LP969,4972.35%$12.6M+2%
State Street Corp958,1672.32%$12.5M-28%
Segall Bryant & Hamill, LLC926,7112.24%$12.1M-4%
Bastion Asset Management Inc.923,2702.23%$10.8M-30%
Pier Capital, LLC806,6781.95%$10.5M+1%
Millennium Management LLC783,1251.90%$10.2M+21%
Renaissance Technologies LLC733,8831.78%$9.5M-9%
Arrowstreet Capital, Limited Partnership692,5341.68%$9M-9%
Paradigm Capital Management Inc671,2001.62%$8.7M-7%
AQR Capital Management LLC589,1571.43%$7.7M+134%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ANGO insiders reported $0 of open-market purchases and $655K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$655K
3 trades, 2 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Oct 29, 2026
Filed Oct 30, 2026

Purchases and sales by month

$344K$344KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 29, 2026Stephen A TrowbridgeCFOSale23,615$12.27$290KForm 4
Oct 28, 2026Stephen A TrowbridgeCFOSale1,720$12.17$20.9KForm 4
Jul 30, 2026Warren Nighan JRVice presidentSale23,370$14.72$344KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Warren Nighan JRSVP Quality and Regulatory–$344KJul 30, 2026
Stephen A TrowbridgeEVP and CFO–$311KOct 29, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ANGO short interest

Low short interest. 4.8% of ANGO shares are sold short: about 1 share in 21. Over the last 12 reports the number of shares short went up 3%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.00M ANGO shares were sold short, 4.8% of the shares outstanding, up 4.5% from the report before. At the average daily volume of 686,981 shares, buying them all back would take about 2.9 trading days (days to cover).

Shares short, % of all shares

4.76%May 15Oct 305.03%

Days to cover

2.9May 15Oct 307.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.00M4.76%+5%686,9812.9
Oct 15, 20261.92M4.56%+48%1.31M1.5
Sep 30, 20261.29M3.13%-4%581,4012.2
Sep 15, 20261.34M3.25%-1%385,9903.5
Aug 31, 20261.36M3.30%+1%252,4675.4
Aug 14, 20261.35M3.27%+11%552,5472.5
Jul 31, 20261.22M2.96%-7%485,0942.5
Jul 15, 20261.32M3.18%-3%592,1462.2
Jun 30, 20261.36M3.29%-23%469,5752.9
Jun 15, 20261.76M4.25%-7%288,4756.1
May 29, 20261.89M4.57%-3%310,6696.1
May 15, 20261.95M4.72%-6%278,5297.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded ANGO

Since Nov 17, 2024, 1 member of Congress reported 1 purchase and 2 sales of ANGO. The latest was a sale by Debbie Wasserman Schultz on Oct 20, 2025, reported Oct 24, 2025.

Purchases 1Sales 2

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Oct 20, 2025Debbie Wasserman Schultz (D-FL)Sale$2KChildOct 24, 2025Report
Jul 16, 2025Debbie Wasserman Schultz (D-FL)Sale$1K–$15KSelfJul 25, 2025Report
Jun 27, 2025Debbie Wasserman Schultz (D-FL)Purchase$1K–$15KChildJul 25, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Angiodynamics company events

Angiodynamics filed 8 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 8, 2026.

  1. Oct 8, 2026ResultsReleased financial results. Filing
  2. Oct 8, 2026LeadershipBelow, which is incorporated by reference into this Item 1.01. Filing
  3. Jul 14, 2026ResultsReleased financial results. Filing
  4. Apr 23, 2026AnnouncementAngioDynamics, Inc. filed a complaint commencing a patent infringement lawsuit in the United States District Court for the District of Delaware against Endovascular Engineering, Inc. Filing
  5. Apr 2, 2026ResultsReleased financial results. Filing
  6. Feb 3, 2026LeadershipIn connection with James C. Clemmer’s previously announced intention to retire from his position as President and Chief Executive Officer of AngioDynamics, Inc. and its subsidiaries (together, the “ Company Group ”), the Company and Mr. Clemmer entered into a Transition and Retirement Agreement… Filing
  7. Jan 14, 2026AnnouncementShared information with investors. Filing
  8. Jan 6, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Angiodynamics financials

Famous investors that hold ANGO

4 of the 50 well-known investors we track reported holding ANGO in their latest 13F filing. The largest position is Steve Cohen's, worth $14.8M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 2026964,953$14.8M0.0%-68%
Jim Simons · Renaissance TechnologiesQ3 2026620,383$9.5M0.0%-15%
Israel Englander · Millennium ManagementQ3 2026522,226$8M0.0%-33%
Ken Griffin · Citadel AdvisorsQ3 202667,392$1M0.0%+440%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ANGO in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Point72 Asset Management, L.P.13G/A2.3%
Nov 16, 2026Point72 Asset Management, L.P.13G/A2.3%

Questions about Angiodynamics Inc (ANGO) stock

Who owns the most ANGO stock?

The largest reported owner of Angiodynamics Inc (ANGO) is BlackRock, Inc., with 9.2% of the company. In total, 162 funds and institutions reported holding ANGO at the end of Q2 2026, together about 94% of the shares. See the largest owners.

Are ANGO insiders buying or selling?

In the last 12 months, ANGO insiders reported no open-market purchases and 3 sales worth $655K. The latest trade was on Oct 29, 2026. See every trade.

What is the short interest in ANGO?

As of Oct 30, 2026, 2.00M ANGO shares were sold short, 4.8% of the shares outstanding, up 4.5% from the report before. At the average daily volume of 686,981 shares, buying them all back would take about 2.9 trading days (days to cover). See the history.

Have members of Congress traded ANGO?

Yes. 1 member of Congress reported 1 purchase and 2 sales of ANGO since Nov 17, 2024. The latest was reported on Oct 24, 2025. See the trades.

Which famous investors hold ANGO?

4 of the 50 well-known investors we track reported ANGO in their latest 13F filing, including Steve Cohen, Jim Simons, Israel Englander. The largest position is worth $14.8M. See all holders.

Executive pay

Angiodynamics's chief executive was paid a total of $6.1M for the year ended May 31, 2026, up 10% from $5.5M the year before. In the last 12 months, Angiodynamics's executives and directors bought no stock on the open market and sold $655K.

Chief executive, total pay$6.1MYear ended May 31, 2026. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$13.7MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.8MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.